AbbVie Showcases Breadth And Depth Of Research In Crohn's Disease And Ulcerative Colitis At UEG Week 2023
Portfolio Pulse from Benzinga Newsdesk
AbbVie (NYSE:ABBV) will present new data from its gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress. The data includes late-breaking results from a study comparing SKYRIZI (risankizumab) and STELARA (ustekinumab) in treating moderate to severe Crohn's disease, and analyses from AbbVie's maintenance trials for SKYRIZI and RINVOQ (upadacitinib) in treating Crohn's disease and ulcerative colitis. The company will also present primary efficacy and safety results from the Phase 3 INSPIRE induction study for risankizumab in ulcerative colitis.
October 10, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's presentation of new data on SKYRIZI and RINVOQ at the UEG Week 2023 Congress could potentially impact the company's stock. The data includes results from a head-to-head study comparing SKYRIZI and STELARA in treating Crohn's disease, and analyses from AbbVie's maintenance trials for SKYRIZI and RINVOQ in treating Crohn's disease and ulcerative colitis.
The presentation of new data on SKYRIZI and RINVOQ at a major congress could potentially influence investors' perception of AbbVie's gastroenterology portfolio, thereby impacting the company's stock. Positive results from the studies could boost investor confidence in the company's products and drive up its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100